For example, bladder cancers with Fibroblast Growth Factor Receptor 3 (FGFR3) mutations have shown sensitivity to FGFR inhibitors like erdafitinib, illustrating how genetic data inform therapeutic choices [6]. Here, FGFR3 is linked to urinary bladder cancer.